Original Research

Published on 13 Sep 2024

DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment

in Cancer Immunity and Immunotherapy

Yosuke Ota
Ryosaku Inagaki
Kentaro Sumida
Megumi Nakamura
Yasuhiro Nagai
Setsuko Yamamoto

Frontiers in Oncology

doi 10.3389/fonc.2024.1410373

158 views

Original Research

Accepted on 10 Sep 2024

IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer

in Cancer Immunity and Immunotherapy

lina Somri Gannam
shilhav Meisel Sharon
Shay Hantisteanu
Tomer Bar-Noy
Emiliya Sigal
Gabriel Groisman
Mordechai Hallak
Haim Werner
Ilan Bruchim

Frontiers in Oncology

doi 10.3389/fonc.2024.1410447

Original Research

Accepted on 10 Sep 2024

First-in-Human Phase 1 Dose-Escalation Results With Livmoniplimab, an Antibody Targeting the GARP:TGF-ß1 Complex, as Monotherapy and in Combination With the Anti-PD-1 Antibody Budigalimab in Patients With Advanced Solid Tumors

in Cancer Immunity and Immunotherapy

Toshio Shimizu
John Powderly
Albiruni Ryan Abdul Razak
Patricia Lorusso
Kathy D Miller
Steven Kao
Sarah Kongpachith
Michelle Graham
Brian Stoll
Maulik Patel

Frontiers in Oncology

doi 10.3389/fonc.2024.1376551

Case Report

Accepted on 10 Sep 2024

Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5：a case report and literature review

in Cancer Immunity and Immunotherapy

Qiu Zhao
Min Xiao
Jian Ma
Xiaoqian Li
Minwei Yang
Yanzhi Bi

Frontiers in Oncology

doi 10.3389/fonc.2024.1465664

Original Research

Accepted on 09 Sep 2024

FAS gene expression, prognostic significance and molecular interactions in lung cancer

in Cancer Immunity and Immunotherapy

Kaimin Li
Shing Cheng Tan
Zhihao Yang
Chenwei Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1473515

Case Report

Accepted on 09 Sep 2024

Case Report: Fatal hemoptysis after effective treatment with Tislelizumab and Anlotinib in Pulmonary sarcomatoid carcinoma-a case report

in Cancer Immunity and Immunotherapy

Chen-Wei Pu
Zhen-Zhen Wang
Yong-Fen Ma

Frontiers in Oncology

doi 10.3389/fonc.2024.1445358

Review

Accepted on 09 Sep 2024

Innovative Strategies in Genitourinary Cancer: The Role of Oncolytic Viruses

in Cancer Immunity and Immunotherapy

Jie Zhang
Kepu Liu
Shihao Shang
Wei Di
Yu Zheng
Lei Zhang
Ying Liang
Dongen Ju
Jianlin Yuan

Frontiers in Oncology

doi 10.3389/fonc.2024.1461324

Original Research

Accepted on 09 Sep 2024

Modeling Epithelial-Mesenchymal Transition in Patient-Derived Breast Cancer Organoids

in Cancer Immunity and Immunotherapy

Neta Bar-Hai
Rakefet Ben-Yishay
Sheli Arbili-Yarhi
Naama Herman
Vered Avidan- Noy
Tehillah Menes
Aiham Mansour
Fahim Awwad
Nora Balint-Lahat
Gil Goldinger

Frontiers in Oncology

doi 10.3389/fonc.2024.1470379

Editorial

Accepted on 09 Sep 2024

Editorial: Insights and Implications of Mechanisms Shaping Glioma Immune Landscape, Immunotherapy Resistance, and Relevant Translational Research

in Cancer Immunity and Immunotherapy

Xiangqi Meng
Linlu Tian
Jinquan Cai

Frontiers in Oncology

doi 10.3389/fonc.2024.1485761

Hypothesis and Theory

Published on 06 Sep 2024

Hepatocellular carcinoma cells induce γδ T cells through metabolic reprogramming into tumor-progressive subpopulation

in Cancer Immunity and Immunotherapy

Jinkun Xia
Chaoyu Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1451650

153 views

Original Research

Accepted on 04 Sep 2024

Enhanced Tumor Control and Survival in Preclinical Models with Adoptive Cell Therapy Preceded by Low-Dose Radiotherapy

in Cancer Immunity and Immunotherapy

Nahum Puebla-Osorio
Natalie Fowlkes
Hampartsoum B Barsoumian
Gitika Srivastava
Claudia Kettlun-Leyton
Sara Nizzero
Tiffany Voss
Thomas S Riad
Christina Wong
Ailing Huang

Frontiers in Oncology

doi 10.3389/fonc.2024.1407143

Original Research

Published on 04 Sep 2024

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

in Cancer Immunity and Immunotherapy

Lev Demidov
Galina Kharkevich
Natalia Petenko
Vladimir Moiseenko
Svetlana Protsenko
Tatiana Semiglazova
Anastasia Zimina
Nadezhda Kovalenko
Natalia Fadeeva
Dmitry Kirtbaya

Frontiers in Oncology

doi 10.3389/fonc.2024.1385685

280 views

Original Research

Accepted on 02 Sep 2024

Exploring the Impact of HDL and LMNA Gene Expression on Immunotherapy Outcomes in NSCLC: A Comprehensive Analysis Using Clinical & Gene data

in Cancer Immunity and Immunotherapy

Jingru Li
Jingting Wang
Bangwei Cao

Frontiers in Oncology

doi 10.3389/fonc.2024.1448966

Review

Accepted on 02 Sep 2024

Progression of Oncolytic Virus in Liver Cancer Treatment

in Cancer Immunity and Immunotherapy

Xuesi Hua
Siyu Xuan
Yangyang Tang
Shilin You
Shang Zhao
Ye Qiu
Yinqing Li
Yongqing Li
Yanping Su
Peng Qu

Frontiers in Oncology

doi 10.3389/fonc.2024.1446085

Brief Research Report

Published on 02 Sep 2024

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies

in Cancer Immunity and Immunotherapy

Lara V Graham
Jack Fisher
Amber DP Doyle
Ben Sale
Luis Del Rio
Albert JE French
Neema P Mayor
Thomas R Turner
Steven G.E Marsh
Mark S Cragg

Frontiers in Oncology

doi 10.3389/fonc.2024.1404051

511 views

Review

Accepted on 30 Aug 2024

The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response

in Cancer Immunity and Immunotherapy

Annabel V Manoleras
Erica K Sloan
AESON CHANG

Frontiers in Oncology

doi 10.3389/fonc.2024.1460493

Navigation group

Articles

DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment

IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer

First-in-Human Phase 1 Dose-Escalation Results With Livmoniplimab, an Antibody Targeting the GARP:TGF-ß1 Complex, as Monotherapy and in Combination With the Anti-PD-1 Antibody Budigalimab in Patients With Advanced Solid Tumors

Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5：a case report and literature review

FAS gene expression, prognostic significance and molecular interactions in lung cancer

Case Report: Fatal hemoptysis after effective treatment with Tislelizumab and Anlotinib in Pulmonary sarcomatoid carcinoma-a case report

Innovative Strategies in Genitourinary Cancer: The Role of Oncolytic Viruses

Modeling Epithelial-Mesenchymal Transition in Patient-Derived Breast Cancer Organoids

Editorial: Insights and Implications of Mechanisms Shaping Glioma Immune Landscape, Immunotherapy Resistance, and Relevant Translational Research

Hepatocellular carcinoma cells induce γδ T cells through metabolic reprogramming into tumor-progressive subpopulation

Enhanced Tumor Control and Survival in Preclinical Models with Adoptive Cell Therapy Preceded by Low-Dose Radiotherapy

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Exploring the Impact of HDL and LMNA Gene Expression on Immunotherapy Outcomes in NSCLC: A Comprehensive Analysis Using Clinical & Gene data

Progression of Oncolytic Virus in Liver Cancer Treatment

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies

The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response